Globus Medical ECONOMIC

As of 21 October 2026. Entity scope: Globus Medical, Inc., the US musculoskeletal medical-device group, including controlled NuVasive and Nevro operations where documented.

Supply Chain & Sourcing Relationships

2025-2026 business context. Globus is a Delaware-incorporated medical-device company headquartered in Audubon, Pennsylvania; its filings describe musculoskeletal products and global commercialization, rather than food or agricultural retail.^{1, 2}

• Direct Israeli agricultural/export suppliers: no public evidence identified for Mehadrin, Hadiklaim, Galilee Export, Agrexco successors, or Israeli produce sourcing.
• Importer-of-record structure for Israeli-origin goods: no public evidence identified.
• Seasonal Israeli sourcing: no public evidence identified.
• Third-party/indirect Israeli-origin sourcing: no public evidence identified.
• Medical-device supply/manufacturing in Israel: no public evidence identified of an Israeli Globus manufacturing site. As reviewed in 2026, Globus’s current registrations page identifies audited/registered sites in Audubon, Memphis and Methuen for Globus and San Diego for NuVasive; this page is not a complete global corporate-register substitute.³

Product Origin, Labeling & Regulatory Compliance

• Settlement-origin products: no public evidence identified tying Globus, NuVasive or Nevro products to manufacturing or sourcing in West Bank settlements, East Jerusalem or the Golan Heights.
• Country-of-origin/settlement labeling enforcement: no public evidence identified of an enforcement action or public regulatory citation concerning settlement-origin labeling.
• Corporate policy on occupied/contested-territory sourcing or labeling: No public policy identified in the reviewed sources.
• OHCHR cross-check: Targeted searches did not surface a target-specific entry, but the cited 2023 database PDF could not be independently retrieved. Its scope and company coverage remain unresolved in this audit; no database-wide absence is claimed.

Investment, Capital & Financial Exposure

Historical direct Israeli corporate presence. [pre-2020] Globus SEC subsidiary exhibits named Globus Medical Israel Ltd/Limited in 2012, 2015 and 2018, and the entity was still listed as a subsidiary as of 31 December 2021.^{4, 5, 6, 7} The worker surfaced a registry-mirror status lead, but the page could not be independently retrieved. The alleged company number, address and dissolution dates remain unresolved; no current legal-status conclusion is drawn from that lead.

NuVasive. Globus agreed to acquire NuVasive in February 2023 and completed the merger on 1 September 2023, with NuVasive becoming wholly owned; Globus later recorded total transaction consideration of about $2.604 billion.^{8, 9, 10} NuVasive’s 31 December 2022 significant-subsidiary exhibit did not name an Israeli entity.¹¹ no public evidence identified that the merger brought a named Israeli manufacturing or operating subsidiary into Globus.

Nevro. Nevro’s 2024 Form 10-K disclosed the 6 February 2025 merger agreement with Globus; Globus’s filing specified $5.85 cash per share, and the acquisition closed on 3 April 2025 with Nevro becoming wholly owned.^{12, 13, 14} Nevro’s 2024 subsidiary exhibit listed entities in Switzerland, the UK, Australia, Germany, Costa Rica and the US, with no Israeli entity named.¹⁵ no public evidence identified of an acquired Israeli Nevro operating company.

Current disclosed subsidiary set. Globus’s subsidiary exhibit as of 31 December 2025 names NuVasive and Nevro entities but no Israeli entity.¹⁶ The exhibit says it omits subsidiaries that would not constitute a significant subsidiary in the aggregate, so this is not proof that no immaterial entity, distributor or local registration holder exists.

R&D/innovation centres in Israel: no public evidence identified.

Ownership/controlling capital. Globus’s primary 2026 SEC proxy reports founder/executive chairman David C. Paul with 66.2% combined voting power, while BlackRock and Janus Henderson were listed below 10% of Class A shares.¹⁷ no public evidence identified of Israeli beneficial control, Israeli tax residence or Israeli Preferred Technology Enterprise status for Globus Medical, Inc.

Portfolio/sovereign-bond exposure: no public evidence identified that Globus or its parent holds Israeli sovereign bonds, Israel-focused funds or material portfolio positions in Israeli companies. Globus is not a financial-sector target, and no underwriting or Israel Bonds role was identified.

Operational Presence & Market Activity

Historical physical/legal footprint. The Israeli subsidiary was documented in SEC filings through 2021.⁷ Its current status and address remain unresolved. A possible Sheba Medical Center lead surfaced by the worker could not be independently retrieved and does not establish a paid government contract.

Current Israel office, workforce and tax contribution: No reliable current Israel office, workforce figure, tax contribution or local revenue figure was identified. As reviewed in 2026, Globus’s current contact page confirms its US headquarters and lists international offices, but the reviewed evidence did not establish a current Israeli office.¹⁸

Market positioning: Globus’s 2023 Form 10-K says it markets and sells across the Americas, Europe, Asia, Africa and Australia through direct and distributor sales forces, but it does not provide an Israel-specific market characterization in the reviewed text.¹⁰ No Israel-specific revenue disclosure was identified.

Military/state/settlement activity: no public evidence identified tying Globus, NuVasive or Nevro to IDF/IMOD procurement, military deployment, settlement infrastructure, or sales/services in settlements. Historical corporate ownership does not establish military end use.⁷ The possible Sheba lead remains unresolved.

Post-19 July 2024 / post-November 2024 continuity: No settlement, IDF/IMOD or other relevant state-support activity was identified to test for continuation after those dates. The Nevro acquisition closed in April 2025, but the reviewed Nevro subsidiary disclosures did not identify an Israeli entity.^{15, 14}

Corporate Structure & Foundational Ties

Founding/incorporation. Globus Medical, Inc. is Delaware-incorporated and headquartered in Audubon, Pennsylvania; its 2024 Form 10-K states that the company was founded in 2003.² no public evidence identified that Globus was founded in Israel or has its principal place of management there.

Israeli-nexus factual checks.

• Founded in Israel: no public evidence identified; the company is described as founded in 2003, Delaware-incorporated and headquartered in Pennsylvania.²
• Headquarters/principal management in Israel: No evidence identified; SEC filings identify Audubon, Pennsylvania.^{1, 2}
• Israeli tax residency / PTE status: no public evidence identified.
• Israeli beneficial ownership/control: no public evidence identified; the reviewed primary 2026 SEC proxy shows David C. Paul as the dominant voting holder.¹⁷
• Acquired controlled Israeli operating companies: no public evidence identified. NuVasive’s 2022, Nevro’s 2024 and Globus’s 2025 disclosed subsidiary lists did not name an Israeli operating company.^{11, 15, 16}

State and institutional linkages: no public evidence identified of Israeli state ownership, Israeli government board appointment, critical-infrastructure designation, or an IDF/IMOD contract. The worker’s possible Sheba lead remains unverified and is not used to establish state procurement.

Structural governance ties to Israel: no public evidence identified of a golden share, charter restriction or other governance mechanism tying Globus to the Israeli state.

Profit Repatriation & Economic Contribution

Revenue attribution to Israel: No Israel-specific revenue figure was identified in the reviewed filings. Globus reports worldwide/international operations at broader regional or consolidated levels.^{1, 10}

Profit flows: no public evidence identified showing Israel-specific profit repatriation, intercompany royalties, tax payments or cash flows. Historical ownership of Globus Medical Israel Limited establishes control of an Israeli corporate vehicle, but the reviewed sources do not quantify its revenue, profits or transfers.⁷

Economic ecosystem role: no public evidence identified characterizing Globus, NuVasive or Nevro as a key Israeli employer, sector anchor or national infrastructure provider.